DA
FRTX

DSC Advisors’s Fresh Tracks Therapeutics, Inc. Common Stock FRTX Stock Holding History

DSC Advisors’s Portfolio FRTX Stock Details FRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-96
Closed -$942K – 70
2013
Q2 		$942K Buy
+96
New +$1.06M 0.62% 26

Other funds holding FRTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LM
Litespeed Management New York $48.2M AUM 9.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return

DSC Advisors's FRTX Position: Q3 2013 in Review

DSC Advisors sold out of Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) in Q3 2013, closing a stake of 96 shares — an estimated $942K sold.

DSC Advisors first reported a position in FRTX in Q2 2013 and held it in 1 quarter. The position peaked at $942K in Q2 2013. 83 funds tracked by Wall St. Rank hold FRTX as of Q3 2013.

  • DSC Advisors reported no remaining Fresh Tracks Therapeutics, Inc. Common Stock position as of Q3 2013 after selling out during the quarter.
  • DSC Advisors sold 96 Fresh Tracks Therapeutics, Inc. Common Stock shares in Q3 2013, an estimated $942K.
  • DSC Advisors first reported a position in Fresh Tracks Therapeutics, Inc. Common Stock in Q2 2013 and held it in 1 quarter.
  • DSC Advisors's Fresh Tracks Therapeutics, Inc. Common Stock position peaked at $942K in Q2 2013.
  • 83 funds tracked by Wall St. Rank held Fresh Tracks Therapeutics, Inc. Common Stock as of Q3 2013.

Based on DSC Advisors's 13F filing for Q3 2013, filed 14 Nov 2013.